Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Digital content
NEWS #PharmaBuzz
27 Aug 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/nykode-sticks-its-neck-out-betting-future-phase-2-cancer-trial-after-losing-genentech-pact
09 Nov 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/surprise-termination-genentech-drops-nykode-partnership-individualized-cancer-vaccine
01 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/01/2679929/0/en/Nykode-Therapeutics-Announces-Expansion-of-Clinical-Collaboration-with-Roche-to-Evaluate-VB10-16-in-Combination-with-anti-PD-L1-in-the-next-trial-in-Advanced-Cervical-Cancer.html
30 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/30/2678651/0/en/Nykode-Therapeutics-to-Present-at-Jefferies-Healthcare-Conference.html
18 Apr 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/04/18/2649342/0/en/Nykode-Therapeutics-announces-positive-final-results-from-its-Phase-2-trial-of-VB10-16-in-combination-with-PD-L1-inhibitor-atezolizumab-in-advanced-cervical-cancer.html
22 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/22/2613021/0/en/Nykode-Therapeutics-to-announce-financial-results-for-the-fourth-quarter-2022-and-host-webcast-presentation-on-February-28-2023.html
Drugs in Development
Details:
Nykode regains control of VB10.NEO cancer vaccine program, a proprietary individualized neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors.
Lead Product(s): VB10.NEO,Bempegaldesleukin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Genentech
Deal Size: $715.0 million Upfront Cash: $200.0 million
Deal Type: Termination November 08, 2024
Lead Product(s) : VB10.NEO,Bempegaldesleukin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Genentech
Deal Size : $715.0 million
Deal Type : Termination
Nykode Therapeutics to Regain Control of VB10.NEO Program
Details : Nykode regains control of VB10.NEO cancer vaccine program, a proprietary individualized neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $200.0 million
November 08, 2024
Details:
VB10.16 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HPV-associated Uterine Cervical Neoplasms.
Lead Product(s): VB10.16
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: F. Hoffmann-La Roche | GOG Foundation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 25, 2023
Details : VB10.16 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HPV-associated Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 25, 2023
Details:
VB10.16 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HPV-associated Oropharyngeal Neoplasms.
Lead Product(s): VB10.16,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2023
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VB10.16 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HPV-associated Oropharyngeal Neoplasms.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 30, 2023
Details:
The collaboration aims to cover evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer. Nykode will sponsor the trial, and Roche will provide atezolizumab.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 01, 2023
Lead Product(s) : VB10.16,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The collaboration aims to cover evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer. Nykode will sponsor the trial, and Roche will p...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2023
Details:
VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate targeting antigens to antigen presenting cells. It is in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2023
Lead Product(s) : VB10.16,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate targeting antigens to antigen presenting cells. It is in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2023
Details:
Based on the positive interim data and in line with our potential registrational trial strategy, we look forward to starting the VB-C-04 trial in the U.S. The trial is aimed at providing a fast path to making VB10.16 available to patients.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: GOG Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2023
Lead Product(s) : VB10.16,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GOG Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Based on the positive interim data and in line with our potential registrational trial strategy, we look forward to starting the VB-C-04 trial in the U.S. The trial is aimed at providing a fast path to making VB10.16 available to patients.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 10, 2023
Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The drug candidate has reported interim data from VB-C-02, a Phase 2 trial in heavily pre-treated cervical cancer patients.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2022
Lead Product(s) : VB10.16,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The drug candidate has reported interim data from VB-C-02, a Phase 2 trial in heavily pre-treated cervical cancer patients.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 20, 2022
Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Lead Product(s): VB10.16,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Sponsor: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2022
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : MSD Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 06, 2022
Details:
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer.
Lead Product(s): VB10.16,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2022
Lead Product(s) : VB10.16,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cer...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 07, 2022
Details:
VB10.NEO is a proprietary individualized DNA-based neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors.
Lead Product(s): VB10.NEO,Bempegaldesleukin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Vaccine
Sponsor: Genentech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2022
Lead Product(s) : VB10.NEO,Bempegaldesleukin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VB10.NEO is a proprietary individualized DNA-based neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
